Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Breast Neoplasms 577Triple Negative Breast Neoplasms 125Neoplasm Metastasis 50Breast Neoplasms, Male 28Ovarian Neoplasms 26Neoplasms 26Inflammatory Breast Neoplasms 22Carcinoma, Non-Small-Cell Lung 19Stomach Neoplasms 14Endometrial Neoplasms 11Carcinoma, Ductal, Breast 11Carcinoma, Ovarian Epithelial 10Pancreatic Neoplasms 9Colorectal Neoplasms 9Melanoma 8Lung Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7HER2-positive Breast Cancer 7Squamous Cell Carcinoma of Head and Neck 6Prostatic Neoplasms 6Esophageal Neoplasms 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 4Brain Neoplasms 4Anatomic Stage I Breast Cancer AJCC v8 4Advanced Breast Cancer 4Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3

Interventions

olaparib 4Carboplatin 2talazoparib 1pembrolizumab 1Surveys and Questionnaires 1Paclitaxel 1Genotype 1Genetic Counseling 1Demography 1Data Collection 1Counseling 1Cognitive Behavioral Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fanconi Anemia, Complementation Group D1 × Paclitaxel × Breast × Clear all
NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Okayama University

Phase 2 Recruiting
23 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡